Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 37, 2024 - Issue 4
Submit an article Journal homepage
26
Views
1
CrossRef citations to date
0
Altmetric
Original Research: Gastroenterology

Close outpatient follow-up associated with reduced readmission rates in patients with inflammatory bowel disease

Phi Trana Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3968-7327
, DOORCID Icon,
Matthew Tjahjaa Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas, USA
, MD,
Yilun Wangb Texas A&M School of Medicine, College Station, Bryan, Texas, USA
,
Nikhil Setha Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas, USA
, MD,
Rylyn Reyesc Division of Gastroenterology, Baylor Scott and White Medical Center, Temple, Texas, USA
,
Charles Bussellc Division of Gastroenterology, Baylor Scott and White Medical Center, Temple, Texas, USA
, MD,
Audrene Edwardsd Baylor Scott and White Research Institute, Dallas, Texas, USA
, MS &
Christopher M. Johnsona Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas, USA;c Division of Gastroenterology, Baylor Scott and White Medical Center, Temple, Texas, USA;e Baylor College of Medicine, Temple, Texas, USA
, MD, PhD show all
Pages 517-524 | Received 22 Nov 2023, Accepted 18 Mar 2024, Published online: 09 Apr 2024

  • George LA, Martin B, Gupta N, Shastri N, Venu M, Naik AS. Predicting 30-day readmission rate in inflammatory bowel disease patients: performance of LACE index, Crohn’s & Colitis 360. 2019;1(1):otz007. doi:10.1093/crocol/otz007.
  • Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008;14:352–362.
  • Naylor MD, Brooten D, Campbell R, et al. Comprehensive discharge planning and home follow-up of hospitalized elders: a randomized clinical trial. JAMA. 1999;281(7):613–620. doi:10.1001/Jama.281.7.613.
  • Malhotra A, Phatharacharukul P, Thongprayoon C. Risk factors for 90-day readmission in veterans with inflammatory bowel disease—does post-discharge follow-up matter? Mil Med Res. 2018;85(1):5. doi:10.1186/s40779-018-0153-x.
  • Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(9):1939–1948.e7. doi:10.1016/j.cgh.2019.08.042.
  • Ghahramani S, Tamartash Z, Sayari M, et al. Risk factors affecting 90-day readmission of patients with inflammatory bowel disease. Middle East J Dig Dis. 2022;14(1):34–43. doi:10.34172/mejdd.2022.253.
  • Barnes EL, Kochar B, Long MD, et al. Modifiable risk factors for hospital readmission among patients with inflammatory bowel disease in a nationwide database. Inflamm Bowel Dis. 2017;23(6):875–881. doi:10.1097/MIB.0000000000001121.
  • White EC, Melmed GY, Vasiliauskas E, et al. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn’s disease? Dis Colon Rectum. 2012;55(5):563–568. doi:10.1097/DCR.0b013e3182468961.
  • Law CCY, Sasidharan S, Rodrigues R, et al. Impact of specialized inpatient IBD care on outcomes of IBD hospitalizations. Inflamm Bowel Dis. 2016;22(9):2149–2157. doi:10.1097/mib.0000000000000870.
  • Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol. 2008;103(11):2789–2798. doi:10.1111/j.1572-0241.2008.02054.x.
  • Kaplan GG, McCarthy EP, Ayanian JZ, et al. Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology. 2008;134(3):680–687. doi:10.1053/j.gastro.2008.01.004.
  • Nguyen NH, Zhang X, Long MD, Sandborn WJ, Kappelman MD, Singh S. Patient-reported outcomes and risk of hospitalization and readmission in patients with inflammatory bowel diseases. Dig Dis Sci. 2022;67(6):2039–2048. doi:10.1007/s10620-021-07082-3.
  • Gavish R, Levy A, Dekel OK, Karp E, Maimon N. The association between hospital readmission and pulmonologist follow-up visits in patients with COPD. Chest. 2015;148(2):375–381. doi:10.1378/chest.14-1453.
  • Jackson C, Shahsahebi M, Wedlake T, DuBard CA. Timeliness of outpatient follow-up: an evidence-based approach for planning after hospital discharge. Ann Fam Med. 2015;13(2):115–122. doi:10.1370/afm.1753.
  • Bergethon KE, Ju C, DeVore AD, et al. Trends in 30-day readmission rates for patients hospitalized with heart failure: Findings from the Get with the Guidelines-Heart Failure registry. Circ Heart Fail. 2016;9(6):10–1161. e002594. doi:10.1161/CIRCHEARTFAILURE.115.002594.
  • Mudireddy P, Scott F, Feathers A, Lichtenstein GR. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. Inflamm Bowel Dis. 2017;23(10):1832–1839. doi:10.1097/MIB.0000000000001242.
  • Poojary P, Saha A, Chauhan K, et al. Predictors of hospital readmissions for ulcerative colitis in the United States: a national database study. Inflamm Bowel Dis. 2017;23(3):347–356. doi:10.1097/MIB.0000000000001041.
  • Tak HJ, Goldsweig AM, Wilson FA, et al. Association of post-discharge service types and timing with 30-day readmissions, length of stay, and costs. J Gen Intern Med. 2021;36(8):2197–2204. doi:10.1007/s11606-021-06708-6.
  • Dahiya DS, Perisetti A, Kichloo A, et al. Increasing thirty-day readmissions of Crohn’s disease and ulcerative colitis in the United States: a national dilemma. World J Gastrointest Pathophysiol. 2022;13(3):85–95. doi:10.4291/wjgp.v13.i3.85.
  • Faleck DM, Winters A, Chablaney S, et al. Shorter disease duration is associated with higher rates of response to Vedolizumab in patients with Crohn’s disease but not ulcerative colitis. Clin Gastroenterol Hepatol. 2019;17(12):2497–2505.e1. doi:10.1016/j.cgh.2018.12.040.
  • Berg DR, Colombel J-F, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896–1905. doi:10.1093/ibd/izz059.
  • Feagan BG, Rubin DT, Danese S, et al. Efficacy of Vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2017;15(2):229–239.e5. doi:10.1016/j.cgh.2016.08.044.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.